GW Pharmaceuticals plc: GW Pharmaceuticals to Report Q3 2014 Financial Results and Host Conference Call on 6 August, 2014

Tickers: GWPH
LONDON, July 30, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 6 August, 2014 its third quarter financial results for the period ending 30 June, 2014. GW will also host a conference call the same day at 1:00 p.m. BST (8:00 a.m. EDT).

Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Wal-Mart Stores, Inc.
About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received from the FDA Fast Track Designation for the treatment of Dravet syndrome and Orphan Drug Designation from the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy syndromes. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type-2 diabetes, and schizophrenia.www.gwpharm.com.

CONTACT: GW Pharmaceuticals plc

         (Today) +44 20 3727 1000

         

         Justin Gover, CEO

         +44 1980 557000

         

         Stephen Schultz, VP Investor Relations

         + 1 401 500 6570 or + 1 917 280 2424

         

         FTI Consulting

         

         Ben Atwell / Simon Conway / John Dineen

         (European media enquiries)

         + 44 20 3727 1000

         

         Robert Stanislaro (US media enquiries)

         +1 212 850 5657

         

         Trout Group, LLC (US investor relations)

         

         Todd James / Chad Rubin

         +1 646 378 2900

distributed by

This noodl was issued by GW Pharmaceuticals plc and was initially posted at www.gwpharm.com. It was distributed, unedited and unaltered, by noodls on 2014-07-30 14:57:41 UTC. The issuer is solely responsible for the accuracy of the information contained therein.